Hologic Received FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio
On February 04, 2026, Hologic, Inc. announced that its Aptima® HPV Assay had received FDA approval for clinician-collected HPV primary screening. The test, which was the only FDA-approved mRNA-based assay at the time, had been specifically designed to detect infections most likely to lead to cervical cancer.
Screening for cervical cancer has been critically important for women’s health. In the United States, it was estimated that in 2026, around 13,490 new cases of invasive cervical cancer would be diagnosed, and approximately 4,200 women would...